Loss of Bcl-2 expression in Barrett's dysplasia and adenocarcinoma is associated with tumor progression and worse survival but not with response to neoadjuvant chemoradiation.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Diseases of the esophagus

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/J.1442-2050.2003.00281.XPMID 12581249
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical practice. Barrett's Esophagus.

  2002cited by this paper
• Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer

  2002cited by this paper
• Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer

  2001cited by this paper
• Spontaneous and inducible apoptosis in oesophageal adenocarcinoma

  2001cited by this paper
• A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy.

  2001cited by this paper
• Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma

  2000cited by this paper
• Bax and Bcl‐2 protein expression following radiation therapy versus radiation plus thermoradiotherapy in stage IIIB cervical carcinoma

  2000cited by this paper
• Immunohistochemical status of the p53 protein and Ki-67 antigen using biopsied specimens can predict a sensitivity to neoadjuvant therapy in patients with esophageal cancer.

  2000cited by this paper
• Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.

  1999cited by this paper
• Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer

  1998cited by this paper
• Apoptosis is inhibited early in the dysplasia-carcinoma sequence of Barrett esophagus.

  1997cited by this paper
• Expression of bcl‐2 protein in esophageal squamous cell carcinomas and its association with lymph node metastasis

  1997cited by this paper
• The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years.

  1997cited by this paper
• Apoptosis and immunohistochemical bcl‐2 expression in colorectal adenomas and carcinomas: Aspects of carcinogenesis and prognostic significance

  1996cited by this paper
• A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.

  1996cited by this paper
• The Significance of c-erb B‐2 and p53 Immunoreactivity in Patients with Adenocarcinoma of the Esophagus

  1995cited by this paper
• Expression and prognostic significance of Bcl-2 in ovarian tumours.

  1995cited by this paper
• Bcl-2 and the regulation of programmed cell death

  1994cited by this paper
• Expression of epidermal growth factor receptor and proliferating cell nuclear antigen predicts response of esophageal squamous cell carcinoma to chemoradiotherapy

  1994cited by this paper
• Bcl-2 protein expression and long-term survival in breast cancer.

  1994cited by this paper
• Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.

  1993cited by this paper
• Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction.

  1993cited by this paper
• bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death.

  1993cited by this paper
• Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas.

  1993cited by this paper
• bcl-2 protein in non-small-cell lung carcinoma.

  1993cited by this paper
• Incidence of cancer in esophageal columnar metaplasia (Barrett’s esophagus)

  1992cited by this paper
• Apoptosis induced by anticancer drugs

  1992cited by this paper
• Rising incidence of adenocarcinoma of the esophagus and gastric cardia.

  1991cited by this paper
• Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death

  1990cited by this paper
• Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings.

  1990cited by this paper
• Adenocarcinoma of the Oesophagus and Ectopic Gastric Mucosa

  1952cited by this paper

• MicroRNA Dysregulation and Therapeutic Opportunities in Esophageal Diseases.

  2023cites this paper
• CRITICAL REVIEW: BARRETS OESOPHAGUS – METAPLASIA – DYSPLASIA – MALIGNANT TRANSFORMAYION PHENOTYPICAL CHARACTERISTICS AND PROGRESSION MARKERS

  2022cites this paper
• Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma

  2021cites this paper
• INVESTIGATION OF THE POSSIBLE EFFECT OF S-ALLYL-L-CYSTEINE ON APOPTOSIS AND AUTOPHAGY IN HUMAN LEUKEMIA CELL LINE

  2021cites this paper
• Differential MicroRNA Signatures in the Pathogenesis of Barrett's Esophagus

  2020cites this paper
• 2 Gastroesophageal Reflux Disease : Molecular Predictors in Neoplastic Progression of Barrett ’ s Esophagus

  2017cites this paper
• 52. Barrett Esophagus and Esophageal Adenocarcinoma

  2015cites this paper
• ABT-263 induces apoptosis and synergizes with chemotherapy by targeting stemness pathways in esophageal cancer

  2015cites this paper
• Place du modèle de reflux duodéno-oesophagien induit chirurgicalement chez le rat dans la compréhension de la carcinogenèse oesophagienne. Vers l’identification d’outils diagnostiques précoces et thérapeutiques

  2013cites this paper
• GERD—Barrett—Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?

  2013cites this paper
• High p53 and MAP1 light chain 3A co-expression predicts poor prognosis in patients with esophageal squamous cell carcinoma.

  2013cites this paper
• Early Diagnostic Biomarkers for Esophageal Adenocarcinoma—The Current State of Play

  2013cites this paper
• Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction

  2013cites this paper
• Gastroesophageal Reflux Disease: Molecular Predictors in Neoplastic Progression of Barrett's Esophagus

  2012cites this paper
• Immunohistochemical Expression of Ki-67, PCNA, pRb, p16, p53, Bcl-2 and Bax in Esophageal Adenocarcinoma and Barrett’s Associated Dysplasia

  2012cites this paper
• Chapter 14 – Immunohistology of the Gastrointestinal Tract

  2011cites this paper
• Hormonal and reproductive factors and risk of esophageal cancer in Chinese postmenopausal women: a case-control study.

  2011cites this paper
• {2-[(3-Carboxy-1-oxopropyl) amino]-2-deoxy-d-Glucose} suppresses proliferation and induces apoptosis in the human esophageal cancer cell line

  2011cites this paper
• Avaliação de fatores de estadiamento em carcinoma epidermoide do esôfago e de fatores imuno-histoquímicos relacionados a apoptose e p53

  2011cites this paper
• Reply to Letter to the Editor: Re: Comparison of COX-2, Ki-67, and BCL-2 expression in normal esophageal mucosa, Barrett’s esophagus, dysplasia, and adenocarcinoma with postablation mucosa and implications for ablative therapies (Online First)

  2011cites this paper
• The Histological and Immunohistochemical Aspects of Bile Reflux in Patients with Gastroesophageal Reflux Disease

  2011influential citation
• Expression of Bcl-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy.

  2010cites this paper
• Reproductive and sex hormonal factors and oesophageal and gastric junction adenocarcinoma: a pooled analysis.

  2010cites this paper
• Genetics in the Pathogenesis of Esophageal Cancer: Possible Predictive and Prognostic Factors

  2010cites this paper
• Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis.

  2010cites this paper
• Genesis of Barrett’s Neoplasia: Current Concepts

  2010cites this paper
• Apoptosis in Carcinogenesis and Chemotherapy

  2009cites this paper
• Adenocarcinoma of the esophagogastric junction: relationship between clinicopathological data and p53, cyclin D1 and Bcl-2 immunoexpressions.

  2009cites this paper
• Potential role of NF-kappaB in esophageal adenocarcinoma: as an emerging molecular target.

  2009cites this paper
• Unlike esophageal squamous cells, Barrett's epithelial cells resist apoptosis by activating the nuclear factor-kappaB pathway.

  2009cites this paper
• Apoptosis in Carcinogenesis and Chemotherapy – Esophageal Cancer

  2009cites this paper
• Barrett esophagus and esophageal adenocarcinoma

  2009cites this paper
• Prognostication in esophageal cancer

  2008cites this paper
• Interplay between oncoproteins and antioxidant enzymes in esophageal carcinoma treated without and with chemoradiotherapy: a prospective study.

  2008cites this paper
• Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome.

  2008cites this paper
• Molecular Prognostic Factors in Adenocarcinoma of the Esophagus and Gastroesophageal Junction

  2007cites this paper
• Bax upregulation may provide a rationale for the low incidence of esophageal adenocarcinoma in a Greek cohort of patients with Barrett's esophagus.

  2007cites this paper
• Biomarkers in Barrett's oesophagus and oesophageal adenocarcinoma.

  2007cites this paper
• Molecular basis of Barrett’s oesophagus and oesophageal adenocarcinoma

  2006cites this paper
• with a proapoptotic Bax to Bcl-2 ratio associated neoplasia in Barrett's oesophagus and is MUC4 is increased in high grade intraepithelial

  2006cites this paper
• Chapter 13 – Immunohistochemistry of the Gastrointestinal Tract, Pancreas, Bile Ducts, Gallbladder and Liver

  2006cites this paper
• Increasing cyclooxygenase‐2 (cox‐2) gene expression in the progression of Barrett's esophagus to adenocarcinoma correlates with that of Bcl‐2

  2006cites this paper
• Clinicopathologic factors predicting complete pathological response to neoadjuvant chemoradiotherapy in esophageal cancer.

  2006cites this paper
• New molecular concepts of Barrett's esophagus: clinical implications and biomarkers.

  2005influential citation
• The molecular biology of esophageal adenocarcinoma

  2005cites this paper
• Barrett’s Esophagus: a Molecular Characterization

  2005cites this paper
• Peptide YY inhibits the growth of Barrett's esophageal adenocarcinoma in vitro.

  2004cites this paper
• MUC4 is increased in high grade intraepithelial neoplasia in Barrett’s oesophagus and is associated with a proapoptotic Bax to Bcl-2 ratio

  2004cites this paper
• High p 53 and MAP 1 light chain 3 A co-expression predicts poor prognosis in patients with esophageal squamous cell carcinoma

  year unknowncites this paper